Intraperitoneal Injection of Graphene Oxide Nanoparticle Accelerates Stem Cell Therapy Effects on Acute Kidney Injury.
graphene oxide
kidney injury
stem cell
Journal
Stem cells and cloning : advances and applications
ISSN: 1178-6957
Titre abrégé: Stem Cells Cloning
Pays: New Zealand
ID NLM: 101535817
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
04
2019
accepted:
10
01
2020
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
28
2
2020
Statut:
epublish
Résumé
Graphene-based nanostructures have shown some degree of stem cell protection against cell death. Acute kidney injury (AKI) is a major cause of mortality in hospitalized patients. Here, graphene oxide (GO) was used to improve the efficacy of bone marrow-derived mesenchymal stem cells (MSCs) in the treatment of AKI induced by cisplatin, a chemotherapy medication used to treat a number of cancers. Cisplatin-induced AKI was modeled in male rats. Intraperitoneal injection of MSCs mixed with GO, synthesized by graphite powder, H Administration of GO nanoparticles suspended in MSCs reduced serum levels of creatinine (Cr) and blood urea nitrogen (BUN) in cisplatin-induced AKI in the experimental group compared to the control group. Histopathological evaluation also showed an improvement of morphological alterations of kidney, such as cellular proliferation, apoptosis and necrosis, cyst formation and intratubular debris in the experimental group compared to the control group. Our data revealed that GO injection alone without MSCs accelerated the improvement of the kidney injury induced by cisplatin. This study demonstrated that suspended GO could enhance the efficacy of stem cells in the treatment of AKI. GO alone without stem cell accelerates the improvement of cisplatin-induced AKI.
Identifiants
pubmed: 32104004
doi: 10.2147/SCCAA.S212087
pii: 212087
pmc: PMC7023909
doi:
Types de publication
Journal Article
Langues
eng
Pagination
21-32Informations de copyright
© 2020 Foroutan et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
J Clin Invest. 2004 Jul;114(1):5-14
pubmed: 15232604
Chem Commun (Camb). 2010 Apr 14;46(14):2376-8
pubmed: 20309457
Biomed Mater. 2017 Jul 04;12(4):045003
pubmed: 28425919
Vet Sci. 2019 Jun 27;6(3):
pubmed: 31252551
Biomed Res Int. 2014;2014:212149
pubmed: 24592382
Exp Toxicol Pathol. 2013 Jul;65(5):595-600
pubmed: 22727565
Trends Biotechnol. 2011 May;29(5):205-12
pubmed: 21397350
Adv Mater. 2011 Sep 22;23(36):H263-7
pubmed: 21823178
Kidney Int. 2008 May;73(9):994-1007
pubmed: 18272962
Biomaterials. 2014 Aug;35(25):7022-31
pubmed: 24854092
Annu Rev Med. 2008;59:311-25
pubmed: 17914926
Stem Cells. 2008 Aug;26(8):2075-82
pubmed: 18499895
Afr J Tradit Complement Altern Med. 2013 May 16;10(4):88-93
pubmed: 24146507
Biochem Biophys Res Commun. 2014 Sep 12;452(1):174-80
pubmed: 25152405
Biomaterials. 2013 Apr;34(11):2787-95
pubmed: 23340196
J Biomed Mater Res A. 2013 Dec;101(12):3520-30
pubmed: 23613168
ACS Nano. 2010 Oct 26;4(10):5731-6
pubmed: 20925398
Acc Chem Res. 2013 Oct 15;46(10):2211-24
pubmed: 23480658
Urol J. 2016 Jun 28;13(3):2707-16
pubmed: 27351327
Nano Res. 2008;1(3):203-212
pubmed: 20216934
J Biomed Mater Res A. 2018 Jan;106(1):293-303
pubmed: 28891194
Bioconjug Chem. 2011 Dec 21;22(12):2558-67
pubmed: 22034966
J Mol Cell Cardiol. 2011 Feb;50(2):280-9
pubmed: 20727900
Adv Healthc Mater. 2013 Aug;2(8):1072-90
pubmed: 23526812
Nano Lett. 2008 Mar;8(3):902-7
pubmed: 18284217
Nanoscale Res Lett. 2011 Dec;6(1):8
pubmed: 27502632
Indian J Pathol Microbiol. 2011 Oct-Dec;54(4):688-91
pubmed: 22234091
J Am Soc Nephrol. 2007 Sep;18(9):2486-96
pubmed: 17656474
Materials (Basel). 2015 Dec 11;8(12):8674-8690
pubmed: 28793737
Food Chem. 2018 Apr 15;245:1018-1024
pubmed: 29287317
Chem Soc Rev. 2010 Jan;39(1):228-40
pubmed: 20023850
ACS Nano. 2015 May 26;9(5):4987-99
pubmed: 25919434
Science. 2008 Jul 18;321(5887):385-8
pubmed: 18635798